Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
28. März 2024 09:03 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement...
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
04. März 2024 09:09 ET
|
Endonovo Therapeutics, Inc.
US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed...
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
04. Dezember 2023 09:15 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives...
Endonovo's SofPulse® Secures Taiwan FDA Approval
12. Oktober 2023 09:07 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product,...
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
22. August 2023 09:07 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a US-based commercial medical device company -- today announced its inclusion on the Federal Supply...
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
08. August 2023 09:03 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first...
Endonovo Pending Agreement to Develop Telehealth Division
07. Juni 2023 09:07 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 07, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), an industry leading medical technology company, is working with a prominent developer of telehealth...
Endonovo Launches SofPulse® into the Veterans Administration
02. Mai 2023 09:03 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 02, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) a US-based biotechnology developer, today announced the launch of SofPulse® with Academy Medical, Inc., a...
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
25. April 2023 09:07 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical...
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
13. April 2023 09:07 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 13, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership...